ABCL vs IT · rev $28.8M vs P/E 16, rev $6.27B
Abcellera Biologics Inc (ABCL) versus Gartner Inc (IT) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Gartner Inc (IT) is a information technology services company listed on US.
Latest reported ABCL revenue for 2024-12-31 was $28.8M. Net income was -$162.9M. Revenue was down 24.2% from 2023-12-31 to 2024-12-31. ABCL currently screens at market cap $1.12B.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
ABCL currently screens at market cap $1.12B. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Not investment advice. Open the ABCL and IT stock pages for the full models.
Not investment advice.